Gain Therapeutics is a preclinical biotechnology company focused on developing new medicines for protein misfolding diseases. Their supercomputer-driven target-based drug discovery platform, “SEE-Tx™,” is a novel approach that uses structural and computational biology to discover previously unidentified allosteric binding sites with high potential for druggability. These sites can be targeted with small molecules for therapeutic benefit to correct enzyme misfolding, thereby restoring function, eliminating toxic substrate, and addressing the underlying cause of disease. SEE-Tx™ is an entirely new drug discovery and development process made possible by Supercomputing with the potential to transform this process into a more efficient method with life changing treatments created in a fraction of the time at a fraction of the cost and for multiple disease target. The platform has been validated through external partnerships with pharmaceutical companies such as Sumitomo Dainippon and has generated all five development candidates currently in Gain’s pipeline. Gain has an initial focus in lysosomal storage diseases and CNS disorders, but the platform is agnostic and can be applied to any disease caused by protein misfolding, including the disease areas of metabolism, immunology, and oncology. The company has an experienced and highly successful Board of Directors and management team with over $30 billion in transactional history, and includes Chairman and co-founder Khalid Islam, Ph.D., who previously was a part of several biotech exits, including Gentium ($1 billion acquisition by Jazz Pharma) and Immunomedics ($21 billion acquisition by Gilead).